Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hillstream BioPharma, Inc. - Common Stock
(NQ:
HILS
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EDT, Sep 22, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Hillstream BioPharma, Inc. - Common Stock
Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis
November 06, 2023
Via
ACCESSWIRE
Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.
September 22, 2023
Via
ACCESSWIRE
Hillstream BioPharma’s Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
April 12, 2023
Via
ACCESSWIRE
Sidoti's January Micro-Cap Conference
January 17, 2023
Via
ACCESSWIRE
Hillstream BioPharma Provides Business Review with Key Pipeline Updates
February 14, 2022
Continued development and validation of HSB-1216 as a leading Ferroptosis inducer to enter the clinic Successful Closing of a $15 million Initial Public Offering on January 14, 2022 R&D Day to Review...
From
Hillstream BioPharma
Via
AccessWire
SAVE THE DATES: Hillstream BioPharma Announces R&D Day on February 24, 2022 and Business Review on Monday February 14, 2022
February 11, 2022
R&D Day on Thursday February 24, 2022 at 8:00 am ET to highlight emerging pipeline assets and anticipated milestones Business Review on Monday February 14, 2022 to highlight key program developments...
From
Hillstream BioPharma
Via
AccessWire
Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc Expression
February 01, 2022
BRIDGEWATER, NJ / ACCESSWIRE / February 1, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting...
From
Hillstream BioPharma
Via
AccessWire
Hillstream BioPharma and University of Massachusetts Chan Medical School Announce Research Collaboration using CRISPR and Computational Approaches to Advance The Hillstream Ferroptomic Atlas
January 26, 2022
Collaboration Aims to Identify Novel Chemogenetic Biomarker Profile of HSB-1216 for Solid Tumors Using CRISPR Mediated Genome Editing to Uncover Novel Targets and Gene Regulatory Networks in...
From
Hillstream BioPharma
Via
AccessWire
Hillstream BioPharma Announces Closing of Initial Public Offering
January 14, 2022
BRIDGEWATER, NJ / ACCESSWIRE / January 14, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting...
From
Hillstream BioPharma
Via
AccessWire
Hillstream BioPharma Announces Pricing of Initial Public Offering
January 11, 2022
BRIDGEWATER, NJ / ACCESSWIRE / January 11, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting...
From
Hillstream BioPharma
Via
AccessWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.